Evolution of Translational Omics: Lessons Learned and the Path Forward (2012)
Chapter: Appendix F: Information Gathering Sessionsand Speakers
Information Gathering Sessions and Speakers
COMMITTEE MEETING 1 – DECEMBER 20, 2010
ROBERT L. BECKER, JR., Chief Medical Officer, Office of In Vitro Diagnostic Device Evaluation and Safety, Center for Devices and Radiological Health, Food and Drug Administration
LISA MCSHANE, Mathematical Statistician, Biometric Research Branch, National Cancer Institute
COMMITTEE MEETING 2 – MARCH 30-31, 2011
KEITH BAGGERLY, Associate Professor of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center
NED CALONGE, Chair, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, and President and CEO, The Colorado Trust
KATRINA KELNER, Editor, Translational Medicine, and Managing Editor, Research Journals, Science Magazine
VÉRONIQUE KIERMER, Executive Editor and Head of Researcher Services, Nature Publishing Group
SUMITHRA MANDREKAR, Associate Professor of Biostatistics, Division of Biomedical Statistics and Informatics, Mayo Clinic
JOSEPH NEVINS, Barbara Levine University Professor of Breast Cancer Genomics, Institute for Genome Sciences and Policy, Duke University
HAROLD PAZ, Chief Executive Officer, Penn State Milton S. Hershey Medical Center, and Senior Vice President for Health Affairs and Dean, College of Medicine, Pennsylvania State University
CHARLES PEROU, Professor of Genetics and Pathology, and Member, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill
PETER PRONOVOST, Director, Division of Adult Critical Care Medicine, Director, Quality and Safety Research Group, and Medical Director, Center for Innovations in Quality Patient Care, Johns Hopkins University
STEVEN SHAK, Chief Medical Officer, Genomic Health
RICHARD SIMON, Chief, Biometric Research Branch, National Cancer Institute
LAURA VAN ‘T VEER, Director, Applied Genomics, and Program Leader, Breast Oncology, Helen Diller Family Comprehensive Cancer Center
SCOTT ZEGER, Professor of Biostatistics and Vice Provost for Research, Bloomberg School of Public Health, Johns Hopkins University
COMMITTEE MEETING 3 – JUNE 30-JULY 1, 2011
LISA MCSHANE, Mathematical Statistician, Biometric Research Branch, National Cancer Institute
TELECONFERENCE 1 – AUGUST 4, 2011
WILLIAM SELLERS, Vice President and Global Head of Oncology, Novartis Institutes for BioMedical Research
TELECONFERENCE 2 – AUGUST 15, 2011
JEFFREY DRAZEN, Editor-in-Chief, New England Journal of Medicine
TELECONFERENCE 3 – AUGUST 19, 2011
ALBERTO GUTIERREZ, Director, Office of In Vitro Diagnostic Device Evaluation and Safety, Center for Devices and Radiological Health, Food and Drug Administration
PANEL DISCUSSION WITH DUKE UNIVERSITY FACULTY AND ADMINISTRATION – AUGUST 22, 2011
WILLIAM BARRY, Assistant Professor of Biostatistics and Bioinformatics
ROBERT CALIFF, Vice Chancellor for Clinical Research and Director, Duke Translational Medicine Institute
MICHAEL CUFFE, Vice President for Ambulatory Services, Chief Medical Officer for Duke University Health System
JOHN FALLETTA, Professor of Pediatrics and Senior Chair, Institutional Review Board
GEOFFREY GINSBURG, Director of Genomic Medicine, Institute for Genome Sciences and Policy
MICHAEL KELLEY, Associate Professor of Medicine, Oncology, and Cancer Protocol Review Committee
SALLY KORNBLUTH, James B. Duke Professor of Pharmacology and Cancer Biology and Vice Dean for Research, Duke University Medical Center
ROSS MCKINNEY, Director, Clinical and Translational Research Ethics, Law, and Policy, Professor of Pediatrics, and Director, Trent Center for Bioethics, Humanities, and Medical History
This page intentionally left blank.
